Epidemiology of hepatocellular carcinoma in Bas-Rhin: Analysis of all incident cases from 1990 to 1999

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 10, 2007, Pages 838-843

  Binder Foucard, Florence ^a   Dofföel, Michel ^b   Velten, Michel ^a,c  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c CENTRE PAUL STRAUSS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; HORMONE;

AGED; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POPULATION; PORTAL VEIN THROMBOSIS; PROPORTIONAL HAZARDS MODEL;

EID: 37149035950     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)73975-1     Document Type: Article

References (27)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0 IARC CancerBase No.5. Lyon, IARCPress, 2001.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.
3. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 majors cancers in 1990. Int J Cancer 1999;83: 18-29.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med 1999;340:745-50.
5. Benhamiche AM, Faivre C, Minello A, Clinard F, Mitry E, Hillon P, et al. Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. J Hepatol 1998;29:802-6.
6. Parkin DM, Whelan S, Ferlay SL, Teppo L, Thomas DB. Cancer incidence in five continents, vol VIII. Lyon: IARC Sci Public no. 155; 2002.
7. Fritz A, Percy C, Jack A, Shanmugaratram K, Sobin L, Parkin DM, et al. International classification of diseases for oncology, Third edition. World Health Organisation, 2000.
8. Estève J, Benhamou E, Raymond L. Méthodes statistiques en épidémiologie descriptive. Paris : Les éditions INSERM ; 1993.
9. Kaplan EL, Meier P. Non parametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
10. Petro R, Pike MC. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics 1973;29:579-84.
11. Cox D. Regression models and life tables. J R Stat Soc 1972;34: 187-220.
12. Remontet L, Buemi A, Velten M, Jougla E, Estève J. Évolution de l'incidence et de mortalité par cancer en France de 1978 à 2000. Éditions de l'InVS, Paris, 2003.
13. Remontet L, Estève J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003;51:3-30.
14. Velasquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma with liver cirrhosis. Hepatology 2003;37:520-7.
15. Even C, Launoy G, Collet T, Duval O, Piquet MA, Rougereau A, et al. Epidémiologie du carcinome hépatocellulaire dans le département du Calvados. Gastroenterol Clin Biol 1997;21:450-8.
16. Trétarre B, Borie F, Bouvier AM, Faivre J, Launoy G, Delafosse P. La prise en charge des cancers primitifs du foie en France. BEH no 43/2004.
17. Dubois F, Desenclos C, Mariotte N, Goudeau A, le groupe d'étude. Séroprévalence de l'infection par le virus de l'hépatite C dans un échantillon national d'assurés sociaux volontaires à un examen de santé de la sécurité sociale. BEH 1996;5:17-9.
18. Gournay J, Monat S, Joubert M, Le Néel JC. Carcinome hépatocellulaire sur foie non cirrhotique. Hépato-Gastro 2000;7:25-32.
19. Le Treut YP, Pons J, Hardwigsen J, Castellani P, Campan P, Hanna X, et al. Carcinome hépatocellulaire sur foie non cirrhotique. Présentation d'une série de 77 patients opérés. Chirurgie 1999;124:485-93.
20. Ganne-Carrié N, Chevret S, Barbare JC, Chaffaud C, Grando V, Vogt AM, et al. Dépistage et traitement précoce du carcinome hépatocellulaire. Enquête concernant les hépato- gastroentérologues en France. Gastroenterol Clin Biol 2002;26:570-7.
21. Roudot-Thoraval F, Dhumeaux D. Vers un dépistage et un traitement précoce du carcinome hépatocellulaire ? Gastroenterol Clin Biol 2002;26:559-60.
22. Bruix J, Shermann M, Llovet JM, Beaugrand M, Lencioni R, Burroughs A, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-30.
23. Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier AM, et al. Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM). Eur J Cancer 2007;43:149-60.
24. Chevret S, Trinchet JC, Mathieu D, Abou Rached A, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999;31:133-41.
25. Gelatti U, Francesco D, Tagger A, Fantoni C, Portlani N, Ribero ML, et al. Etiology of hepatocellular carcinoma influences clinical and pathologic features but not patient survival. Am J Gastroenterol 2003;4:907-14.
26. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okasaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
27. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28:751-5.